Moxilubant maleate
Alternative Names: CGS 25019CLatest Information Update: 26 Aug 2002
At a glance
- Originator Novartis
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics
- Mechanism of Action Leukotriene B4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psoriasis; Rheumatoid arthritis
Most Recent Events
- 30 Nov 1998 CGS 25019C is now called Moxilubant maleate
- 30 Nov 1998 Investigation in Psoriasis in USA (PO)
- 30 Nov 1998 No-Development-Reported for Rheumatoid arthritis in Japan (PO)